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OBJECTIVES This report investigated whether annual changes in body mass index (BMI) are associated with
the opposite changes in prostate-specific antigen (PSA). Previous studies have confirmed lower
PSA levels among men with higher BMI.
METHODS Normal linear mixed models were used to characterize annual PSA, BMI and the ratio of PSA
to BMI profiles for 2641 men undergoing prostate cancer screening for up to 8 years as part of a
San Antonio screening study.
RESULTS Among the 1898 participants (71.9%) who never received a prostate biopsy during the study and
the 585 participants (22.1%) who had one or more biopsies, all negative for prostate cancer, BMI
was higher for Hispanics than other racial groups, lower for older men at study entry, and
increased every year during the study; and PSA and PSA/BMI ratios were higher for older men
at study entry and increased each year on study (all P values .05). Among the 158 men (6.0%)
eventually diagnosed with prostate cancer, no trends in BMI were statistically significant, but
PSA and PSA/BMI ratios were higher on average for older men at study entry and increased each
year on study (both P values .05). Correlations between BMI and PSA changes per year were
negative but not statistically significantly different from zero.
CONCLUSIONS The individual man scrutinizing his PSA and weight year to year can expect a slight annual
increase in both, but changes in PSA from one year to the next cannot be attributed to weight
gain or loss. UROLOGY 78: 10–16, 2011.
© 2011 Elsevier Inc.
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Open access under CC BY-NC-ND license.One in 6 men will be diagnosed with prostatecancer during their lifetime and 1 in 35 will diefrom the disease. In the United States, despite
limitations in sensitivity and specificity, prostate-specific
antigen (PSA) is commonly used for screening for pros-
tate cancer and serves to identify men eligible for more
intensive diagnostic procedures, such as prostate biopsy
for men with PSA levels 4.0 ng/mL. It is now not
ncommon for men to undergo annual screening and to
e familiar with their own track record of PSA. In addi-
ion, at annual doctor visits, men are reacquainted with
heir weight and may also keep track of weight gains or
osses. What is less recognized is the relationship between
hese 2 measures of health. Several studies have con-
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Open access under CC BY-NC-ND license.firmed an inverse association between body mass index
(BMI) and PSA, whereby obese men have lower PSA
levels than nonobese men after controlling for other
potential explanatory factors, including race and ethnic-
ity.1-11 In other words, all other things being equal, an
obese man may have a lower PSA than a nonobese man
and may be less likely to exceed a threshold for referral to
biopsy.12 These associations are cross sectional, compar-
ng average correlations between PSA and BMI among
ifferent men of different weights. The purpose of this
eport was to report average annual changes in PSA and
MI among men undergoing contemporary screening for
rostate cancer, with a particular focus on what a man
ho loses or gains weight can expect in terms of change
n his own PSA.
MATERIAL AND METHODS
The San Antonio Center for Biomarkers of Risk of Prostate
Cancer (SABOR) is an ongoing National Cancer Institute,
Early Detection Research Network-sponsored clinical valida-
tion center enrolling community-dwelling men for annual pros-
tate cancer screening performed by PSA and digital rectal
examination (DRE). Earliest members of the cohort have been
0090-4295/11
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rfollowed for up to 10 years. Men are offered a prostate biopsy as
part of the program if their annual PSA exceeds 2.5 ng/mL,
their DRE examination is suspicious for prostate cancer, or,
selectively, if they have a first-degree relative with prostate
cancer. From this cohort, 2641 men who were enrolled through
May 2009 and had at least one measure of PSA or BMI were
identified for analysis. Of these 2641 men, 1898 (71.9%) never
underwent prostate biopsy during the study period, 585 (22.1%)
underwent prostate biopsy at least once with all biopsies nega-
tive for prostate cancer, and 158 (6.0%) underwent prostate
biopsy at least once and were ultimately diagnosed with prostate
cancer. Among participants who either never received a biopsy
during the study or had one or more negative biopsies, all
available annual PSA and BMI measures were analyzed; among
participants diagnosed (cases), only annual measures before the
time of diagnosis were analyzed. This resulted in a total of 8347
BMI measures and 9244 PSA measures for the 1898 participants
who never received a prostate biopsy, 2986 BMI and 3283 PSA
measures for the 585 participants who had one or more negative
biopsies during the study, and 548 BMI and 648 PSA measures
for participants diagnosed with prostate cancer. For analyses of
longitudinal PSA-to-BMI ratios, only annual visits where both
were recorded were used, resulting in a total of 5755 ratios for
participants who never underwent biopsy, 1616 ratios for partici-
pants with one or more negative prostate biopsies, and 327 ratios
for the participants who were diagnosed with prostate cancer. Age,
race/ethnicity, first-degree family history of prostate cancer, and
history of a prior negative biopsy were recorded for each partici-
pant.
Descriptive statistics were used to summarize participant
characteristics, including age, PSA, BMI and the ratio of PSA
to BMI at first visit, race/ethnicity, family history and prior
negative biopsy history. Characteristics were compared among
the 3 groups of participants (no biopsy, negative biopsy, and
prostate cancer diagnosis) using analysis of variance for contin-
uous measures after statistical diagnostics that assumptions of
normal distributions for observations within groups were satis-
fied. For other categorical characteristics, contingency table
analyses were performed using the chi-square test. Normal lin-
ear mixed models (NLMMs) were fit to natural logarithmically
transformed PSA and BMI values, first separately, and then
together as a bivariate longitudinal model, with choice of fixed
covariates and subject random effects determined by the model
with lowest Bayesian Information Criterion. The same models
were used to fit logarithmically transformed ratios of PSA to
BMI. The random effect structure selected for all models com-
prised a random intercept and linear slope with time since
enrollment. Normal probability plots were used to assess the
normality assumption of within-subject residuals.13 Upon indi-
cation of potentially heavy tails in the residuals, all models
were refit using generalized estimating equations, which do
not rely on the normality assumption. The models gave
nearly identical fits, standard errors, and P values to the
NLMMs, so the results of the NLMMs were considered
sufficiently robust to potential slight violations of normality
and are reported in this analysis. Correlation and associated
95% confidence intervals (CIs) between random PSA and
BMI slopes were estimated using bivariate NLMMs. All
statistical tests were performed at the two-sided 0.05 level of
statistical significance and conducted using the R statistical
package (Version 2.9.0, Copyright 2009, R Foundation for
Statistical Computing).
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Characteristics of participants at study entry are summa-
rized in Table 1. Participants with at least 1 biopsy
performed during the study, including those eventually
diagnosed with cancer, were statistically significantly
older (median 62.3 and 62.1 years for the cancer cases
and participants with at least 1 negative biopsy, respec-
tively, compared with 57.0 years in participants who did
not receive a biopsy during the study, P .001) and had
tatistically significant higher PSA values at entry to the
tudy (median 1.8, 1.5, and 0.8 ng/mL for the 3 groups,
espectively, P .001). Although height at entrance to
the study was constant across the 3 groups of participants
stratified by their biopsy status, the group that never
received a biopsy during the study weighed more (median
195 lb) than either cancer cases (median 192 lb) or men
who subsequently underwent at least 1 biopsy during the
study (median 190 lb) (P .001). A higher proportion of
men diagnosed with cancer were African American
(15.2% compared with 14.0% and 9.1% in the no biopsy
and negative biopsy groups, respectively, P .0001) and
men with a positive family history at study entry were
more likely to have undergone biopsy during the study
(P .001). This latter effect is primarily a screening bias
because as part of a family history substudy, SABOR
participants with a positive family history were intermit-
tently offered a prostate biopsy regardless of PSA and
DRE findings during some of the study years. Participants
diagnosed with prostate cancer were removed from the
cohort upon detection and hence there were fewer years
of follow-up for these men compared with those not
diagnosed (P .001).
Figure 1 shows the wide variation among BMI profiles
and changes in the BMI distributions by year of study
observed among the 3 groups of participants. Among the
majority group of 1898 participants (71.9%) who never
received a biopsy during the study, BMI was statistically
significantly but only mildly lower for older men at study
entry (0.13% lower for each increase in year of age, 95%
CI .05-.21%, P  .001, Fig. 1) and statistically signifi-
cantly higher among Hispanics compared with Cauca-
sians (2.60% higher; 95% CI 0.94-4.29%, P  .015).
African Americans had 2.12% higher BMI values on
average compared with Caucasians, but the difference
was not statistically significant (P .05). BMI increased
by 2.40% with each year on the study for all men who did
not undergo prostate biopsy (95% CI 2.01-2.79%,
P .0001) and increased slightly less per year for older
compared with younger men (increased less 0.04% per
year on study for each increase in year of age of entry
to the study, 95% CI 0.03-0.04%, P .0001, Fig. 1).
Among the second majority group of 585 participants
(22.1%) who underwent at least 1 negative prostate
biopsy during the study, similar trends were seen, but
varied in effect size (Fig. 1). BMI was 0.21% lower for
each increase in year of age at entry to the study (95%
CI .08-.33%, P  .001) and was statistically signifi-
11
cantly higher among Hispanics and African Americans
compared with Caucasians (4.96% higher; 95% CI
2.23-7.77%, and 4.50% higher; 95% CI 0.38-8.80%,
respectively, P  .001). BMI increased only by 1.02%
with year on study for these participants (95% CI
1.09-2.67%, P .0001) and increased slightly less per
Table 1. Characteristics of SABOR participants
Variables
Cancer Cases (n  158)
Partic
Bi
n Statistics n
Age (y) 62.3 (39.8, 84.5)
20-39.9 1 0.6% 67
40-49.9 12 7.6% 450
50-59.9 53 33.5% 759
60-69.9 60 38% 454
70 32 20.3% 168
Height (in) 70 (57, 78)
Weight (lb) 192 (142, 322)
BMI (kg/m2) 27 (21, 46)
24.9 24 15.2% 289
25.0-29.9 83 52.5% 872
30.0-34.9 38 24.0% 504
35.0-39.9 6 3.8% 154
40.0 5 3.2% 77
Missing 2 1.3% 2
PSA (ng/mL) 1.8 (0.2, 8.9)
1 22 13.9% 1157
1-2.5 87 55.1% 641
2.5-4 36 22.8% 81
4-10 13 8.2% 19
10 0 0.0% 0
Missing 0 0.0% 0
PSA/BMI (ng m2/
mL kg)
0.066 (0.005, 0.240)
0.0-0.09 121 76.6% 1832
0.10-0.19 30 19.0% 57
0.20-0.49 5 3.1% 7
0.50-0.85 0 0.0% 0
Missing 2 1.3% 2
Race/Ethnicity
Hispanic 34 21.5% 624
White/non-
Hispanic
99 62.7% 976
Black 24 15.2% 266
Other 1 0.6% 32
Family history
No 115 72.8% 1559
Yes 43 27.2% 339
Number of years
of follow-up
3.2 (0.9, 7.7)
Number of PSA
measures
4 (2, 8)
Number of BMI
measures
3 (0, 8)
Gleason grade
5 3 1.9%
6 105 66.5%
7 34 21.5%
8 4 2.5%
9 4 2.5%
Missing 8 5.1%
Statistics columns refer to the median (range) where the % is not i
annual visit.year for older compared with younger men (increased
12less 0.03% per year on study for each increase in year
of age of entry to the study, 95% CI 0.02-0.04%,
P .0001). For the 158 (6.0%) participants diagnosed
with prostate cancer, there were no statistically signif-
icant effects on BMI.
Figure 2 shows patterns of PSA for the 3 groups of
ts Who Had No
(n  1898)
Participants With at Least
One Negative Biopsy
(n  585) P
ValueStatistics n Statistics
.6 (28.7, 88.5) 62.1 (33.7, 87.5) .001
3.5% 1 0.2%
23.7% 54 9.2%
40.0% 176 30.1%
23.9% 238 40.7%
8.9% 116 19.8%
0 (51, 84) 70 (60, 79) .91
5 (117, 420) 190 (115, 297) .001
8 (17, 54) 27 (20, 45) .001
15.2% 107 18.3%
46.0% 293 50.1%
26.5% 143 24.4%
8.1% 27 4.6%
4.1% 14 2.4%
0.1% 1 0.2%
.8 (0.1, 9.6) 1.5 (0.1, 25) .001
60.9% 188 32.1%
33.8% 211 36.1%
4.3% 86 14.7%
1.9% 89 15.2%
0.0% 9 1.6%
0.0% 2 0.3%
8 (0.002, 0.331) 0.056 (0.004, 0.833) .001
96.5% 419 71.6%
3.0% 112 19.1%
0.4% 46 7.9%
0.0% 5 0.9%
0.1% 3 0.5%
.001
32.9% 151 25.8%
51.4% 376 64.3%
14.0% 53 9.1%
1.7% 5 0.8%
.001
82.1% 421 72.0%
17.9% 164 28.0%
.3 (0.8, 8.2) 6.3 (0.9, 8.2) .001
5 (1, 11) 6 (0, 10) .001
4 (0, 9) 5 (0, 9) .001
ted and the variables from age to family history refer to at the firstipan
opsy
55
7
19
2
0
0.02
5
ndicaparticipants where clear group differences are seen from
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t thethe association of PSA to referral to biopsy in the
SABOR study (higher PSA distributions for men with
one or more negative biopsies compared with men not
referred) and association of PSA with prostate cancer
(higher, rising PSA distributions among men ultimately
diagnosed with prostate cancer compared with those
not). For all 3 groups, only age of entry to the study and
time in the study had statistically significant effects on
PSA. PSA increased by 2.04%, 1.26%, and 1.31% for
each increase in year of age of entry to the study for men
with no biopsy during the study, men with at least 1
negative biopsy, and men diagnosed with prostate cancer,
respectively (95% CI 1.74-2.34%, 0.51-2.02%, and 0.19-
2.44%, respectively, P .0001., P  .001, P  .02,
espectively), and all 3 groups had a statistically signifi-
ant increase in PSA each year of participation in the
tudy (3.15%, 1.02%, and 13.03%, respectively, with
5% CI 2.74-3.56%, 1.54-3.28%, and 10.85-15.26%, re-
pectively, all P .0001). The smaller yearly increases in
he group with negative prostate biopsies than in the
roup with no biopsies is not to be confused with the
igher PSAs observed in the former at any single year of
he study (Fig. 2). Men who ultimately had negative
rostate biopsies typically entered the study with higher
SA values that persistently remained high during the
tudy, which could be a result of benign conditions.
lthough per protocol, the first excess of PSA 2.5
Figure 1. Body mass index distributions for participants wh
nderwent at least 1 prostate biopsy during the study, all ne
ever underwent prostate biopsy during the study (white, n
ncludes all measurements at or beyond Year 6 of the st
istribution, with horizontal lines within the boxes denoting t
imes the interquartile range, and individual points beyondg/mL stipulated a referral to prostate biopsy, there was t
UROLOGY 78 (1), 2011o protocol recommendation for a repeat excess of 2.5
g/mL after a negative prostate biopsy.
Trends in PSA-to-BMI ratios largely reflected those
bserved in PSA (Fig. 3), with statistically significant
ncreases in the ratios by age at study entry for the
articipants who did not undergo biopsy and partici-
ants with one or more negative biopsies, but no
tatistically significant effect by age at study entry
mong men diagnosed with prostate cancer (2.22%
ncrease in the ratio per increase in year of age at study
ntry, 95% CI 1.85-2.59%, P .0001; 1.37%, 95% CI
.39-2.36%, P  .006; and no effect, P  .08, respec-
ively). In all 3 groups there was a statistically signif-
cant increase in the PSA-to-BMI ratios with year on
tudy (2.78% increase per year, 95% CI 2.24-3.33%;
.54%, 95% CI 1.24-3.86%; and 11.91%, 95% CI
.96-14.93%, respectively).
Finally, to address the question of whether changes
bserved in BMI over years on study were associated
hich changes in PSA over the years, correlations be-
ween individually estimated PSA and BMI trajectories
ere estimated by fitting joint NLMMs. For all 3 groups
hese correlations were estimated to be negative, but they
ere small in magnitude and not statistically significantly
ifferent from 0 (correlations  -0.049, -0.048, and -0.17
or participants with no biopsy, negative prostate biop-
ies, and cases diagnosed with prostate cancer, respec-
veloped prostate cancer (black, n  158); participants who
e for prostate cancer (gray, n  585); and participants who
898) by year on study. Year 0 is at study entry and Year 6
Boxes range from the 25th to the 75th quantiles of the
edian; whiskers extend from the edge of the box out to 1.5
whiskers are denoted by asterisks.o de
gativ
 1
udy.
he mively; all P .05).
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In a study of men undergoing annual PSA screening as
part of the Prostate Cancer Prevention Trial (PCPT),
Etzioni et al observed that among a large cohort of 8620
men who did not develop prostate cancer during the 7
years of follow-up, PSA increased annually by 3%, which
is nearly identical to the 2.97% average annual PSA
increase observed among the 2483 men in this study who
did not develop prostate cancer.14 In a study of 24,869
healthy Korean men with initial PSA 4.0 ng/mL, Ham
et al observed an annual PSA increase of 0.02 ng/mL/
year.15 The practical implications for the individual man
undergoing active PSA screening for prostate cancer with
serial testing is that he can expect his PSA to change as
he ages and he may wish to consult his physician regard-
ing the use of conventional age-adjusted PSA cutoff
values.16 However, the magnitude of change in PSA
alue over time (with the PSA assay coefficient of vari-
tion near 3% for PSA levels 3.0 ng/mL) results in
nnual fluctuations of PSA that could overwhelm the
ffects of aging.17,18
BMI slowly increases up until age 50-60 years, where a
gradual decline occurs. Two explanations have been ad-
vanced to explain the lower levels of PSA among obese
men: a hemodilution effect caused by greater blood vol-
Figure 2. Prostate-specific antigen distributions for particip
pants who underwent at least 1 prostate biopsy during th
participants who never underwent prostate biopsy during th
ntry and Year 6 includes all measurements at or beyond
uantiles of the distribution with horizontal lines within the
he box out to 1.5 times the interquartile range, and individ
oints with PSA 15 ng/mL are omitted from the plot forume or suppression of PSA production caused by lower
14testosterone levels and higher estrogen levels among
obese men.7-11
Whether and how an individual’s change in BMI re-
lates to changes in PSA has been less well-studied, but
one cohort study implicated the same negative associa-
tion. In a study of 3341 placebo participants from the
PCPT who were prostate cancer-free at the end of the
study, Kristal et al noted a statistically significant nega-
tive association between weight change and percent
change in PSA over 6 years on trial.19 Specifically, 10 lb
f weight gain over a single year was statistically signifi-
antly associated with a 0.024 ng/mL drop in PSA over
hat year. Repetition of this analysis among the 2483
en in this study who did not develop prostate cancer
evealed strikingly similar results: a statistically signifi-
ant 0.029 ng/mL drop in PSA for a 10-lb weight gain
ver a single year. Although statistically significant, the
agnitude of effect on PSA (0.05 ng/mL) is negligible.
CONCLUSIONS
PSA is currently the ubiquitous tool for screening for
prostate cancer and how or whether it remains so in the
emerging climate of over-diagnosis will soon be realized.
Currently, it is not uncommon for patients to scrutinize
year-to-year fluctuations of PSA as small as 0.1 ng/mL,
who developed prostate cancer (black, n  158); partici-
dy, all negative for prostate cancer (gray, n  585); and
udy (white, n  1898) by year on study. Year 0 is at study
r 6 of the study. Boxes range from the 25th to the 75th
s denoting the median; whiskers extend from the edge of
points beyond the whiskers are denoted by asterisks. Five
y.ants
e stu
e st
Yea
boxe
ualeven though they fall within the measurement error of
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the assays that measure it. As a biological marker, PSA is
influenced by many mechanisms other than prostate can-
cer, so alternations in PSA cannot be solely attributed to
the disease. On the basis of data from a large prostate
cancer screening study with annual follow-up, this report
has confirmed prior findings of statistically significant
inverse associations between PSA and BMI, and a finding
observed from a single prior study, the PCPT, of a sig-
nificant but negligible decrease in PSA among men who
gained 10 lb in one year. However, the SABOR study
experience has revealed no statistically significant corre-
lation between weight changes and PSA changes for the
average man undergoing annual screening for prostate
cancer. In other words, men without prostate cancer who
lose or gain weight over the years should not expect a
corresponding respective noticeable increase or decrease
in PSA.
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